---
title: 'Clinical trial design and treatment effects: a meta-analysis of randomised
  controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and
  indications'
date: '2024-05-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38760158/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240518181526&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Pivotal trial design is significantly associated with measured
  treatment effects. Particularly small, short, single-centre trials testing a new
  drug compared with an inactive rather than an active comparator could overstate
  treatment outcomes. Future studies should verify results in unsuccessful trials,
  adjust for further confounders and examine other therapeutic areas. The FDA, manufacturers
  and trialists must strive to conduct robust clinical trials with a low risk of ...'
disable_comments: true
---
CONCLUSIONS: Pivotal trial design is significantly associated with measured treatment effects. Particularly small, short, single-centre trials testing a new drug compared with an inactive rather than an active comparator could overstate treatment outcomes. Future studies should verify results in unsuccessful trials, adjust for further confounders and examine other therapeutic areas. The FDA, manufacturers and trialists must strive to conduct robust clinical trials with a low risk of ...